GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 7, 2005, 06:55:26 ; Search time 24.409 Seconds
(without alignments)
919.008 Million cell updates/sec

Title: US-09-939-537-35
Perfect score: 288
Sequence: 1 PRASALPAPPTGSALPDPQT.....VISFLLGLGLGVACVLARTR 58

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	288	100.0	58	2	AAR78668	Aar78668 CD7 trans
2	288	100.0	58	2	AAR89440	Aar89440 CD7 trans
3	284	98.6	240	2	AAR20806	Aar20806 Human CD7
4	284	98.6	240	2	AAR91434	Aar91434 Human CD7
5	284	98.6	240	2	AAW80443	Aaw80443 Human CD7
6	284	98.6	240	2	AAW86190	Aaw86190 Human CD7
7	284	98.6	240	3	AAY96129	Aay96129 Human cel
8	284	98.6	240	4	AAU02438	Aau02438 Human lym
9	284	98.6	240	4	AAB36657	Aab36657 Human CD7
10	284	98.6	240	8	ADO49346	Ado49346 Human CD7
11	284	98.6	240	8	ADP55090	Adp55090 Human PRO
12	284	98.6	250	7	ADI60167	Adi60167 Secreted
13	193	67.0	225	8	ADS11080	Ads11080 Human the
14	176	61.1	154	2	AAW35850	Aaw35850 Human CD7
15	83.5	29.0	145	4	ABB71046	Abb71046 Drosophil
16	82	28.5	450	4	ABB71041	Abb71041 Drosophil
17	81.5	28.3	199	4	AAU28370	Aau28370 Novel hum
18	81.5	28.3	199	7	ADE09107	Ade09107 Novel pro
19	81.5	28.3	199	7	ADE09108	Ade09108 Novel pro
20	81	28.1	421	4	ABB67110	Abb67110 Drosophil
21	81	28.1	512	4	ABB61369	Abb61369 Drosophil
22	81	28.1	512	8	ADO00965	Ado00965 Fruit fly
23	80.5	28.0	572	2	AAW31855	Aaw31855 Mycobacte
24	80.5	28.0	763	2	AAW31852	Aaw31852 Mycobacte
25	79.5	27.6	796	7	ADA08003	Ada08003 Human PR
26	79.5	27.6	796	8	ADJ32183	Adj32183 Human PFM
27	78	27.1	116	4	AAM20321	Aam20321 Peptide #
28	78	27.1	116	4	ABB40803	Abb40803 Peptide #
29	78	27.1	116	4	AAM34569	Aam34569 Peptide #
30	78	27.1	116	4	ABB24992	Abb24992 Protein #
31	78	27.1	116	4	AAM74455	Aam74455 Human bon
32	78	27.1	116	4	AAM61662	Aam61662 Human bra
33	78	27.1	116	4	ABG56248	Abg56248 Human liv
34	78	27.1	116	5	ABG44340	Abg44340 Human pep
35	78	27.1	482	7	ABM74077	Abm74077 DNA clone
36	77.5	26.9	192	7	ADM04085	Adm04085 Human pro
37	77	26.7	170	4	AAO13099	Aao13099 Human pol
38	76.5	26.6	85	2	AAY11809	Aay11809 Human 5'
39	76.5	26.6	710	5	ABB91536	Abb91536 Herbicida
40	75	26.0	286	4	ABG19317	Abg19317 Novel hum
41	74.5	25.9	326	8	ADN19906	Adn19906 Bacterial
42	74.5	25.9	772	5	ADR32244	Adr32244 Human tum
43	74.5	25.9	1526	6	ABO14750	Abo14750 Novel hum
44	74	25.7	682	7	ADC31490	Adc31490 Human nov
45	74	25.7	710	7	ADB65248	Adb65248 Human pro

ALIGNMENTS

RESULT 1
AAR78668
ID AAR78668 standard; protein; 58 AA.
XX
AC AAR78668;
XX
DT 11-APR-1996 (first entry)
XX
DE CD7 transmembrane domain.
XX
KW Chimeric receptor; CD4; T-cell receptor; HIV; cytolysis;
KW human immunodeficiency virus; adoptive immunotherapy; CD7.
XX
OS Homo sapiens.
XX
PN WO9521528-A1.
XX
PD 17-AUG-1995.
XX
PF 12-JAN-1995; 95WO-US000454.
XX
PR 14-FEB-1994; 94US-00195395.
PR 02-AUG-1994; 94US-00284391.
XX
PA (GEHO) GEN HOSPITAL CORP.
XX
PI Seed B, Banapour B, Romeo C, Kolanus W;
XX
DR WPI; 1995-292893/38.
DR N-PSDB; AAQ96102.
XX
PT Target cytolysis of HIV-infected cells - by chimeric CD4 receptor-bearing
PT cells.
XX
PS Claim 3; Fig 26; 118pp; English.
XX
CC The CD7 transmembrane domain (AAR78668) is used in the construction of a
CC chimeric receptor utilised in the targeted cytolysis of HIV-infected
CC cells. The chimeric receptor comprises the extracellular domain (pref.
CC amino acids 1-394 or 1-200) of CD4 linked via the CD7 transmembrane
CC domain to an intracellular portion, e.g. of T-cell receptor protein zeta.
CC The CD7 portion of the chimeric receptor is encoded by the DNA sequence
CC given in AAQ96102
XX
SQ Sequence 58 AA;

Query Match 100.0%; Score 288; DB 2; Length 58;
Best Local Similarity 100.0%; Pred. No. 8.5e-22;

```
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58


RESULT 2
AAR89440
ID   AAR89440 standard; peptide; 58 AA.
XX
AC   AAR89440;
XX
DT   26-SEP-1996  (first entry)
XX
DE   CD7 transmembrane domain.
XX
KW   CD7; transmembrane domain; chimeric receptor; CD5; CD34; CH2; CH3; IgG1;
KW   human; CD4; HIV; proteinaceous alpha-helix; T cell; B cell; neutrophil;
KW   dendritic cell; therapy; mammal; infection.
XX
OS   Homo sapiens.
XX
PN   WO9603883-A1.
XX
PD   15-FEB-1996.
XX
PF   26-JUL-1995;   95WO-US009468.
XX
PR   02-AUG-1994;   94US-00284391.
PR   24-FEB-1995;   95US-00394388.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Seed B,  Banapour B,  Romeo C,  Kolanus W;
XX
DR   WPI; 1996-129034/13.
DR   N-PSDB; AAT10779.
XX
PT   Membrane-bound chimeric receptor comprising extracellular portion
PT   including CD4 fragment - cells expressing receptor can be used for
PT   treatment of HIV infection.
XX
PS   Claim 3; Fig 26; 134pp; English.
XX
CC   This sequence represents the CD7 transmembrane domain. This sequence is
CC   included in the membrane bound proteinaceous chimeric receptor of the
CC   invention. Alternatively the transmembrane region of the chimeric
CC   receptor contains a portion of the CD5 or CD34 transmembrane domain. The
CC   extracellular portion of the receptor can also be separated from the
CC   intracellular domain by the hinge, CH2 and CH3 domains of human IgG1. The
CC   extracellular portion of the chimeric receptor contains a fragment of CD4
CC   (amino acids 1-394 or 1-200 of the CD4 sequence) which specifically
CC   recognises and binds HIV-infected cells, but does not mediate HIV
CC   infection. The extracellular domain of the receptor is separated from the
CC   cell membrane by 48 or 72 angstroms, or by one or more proteinaceous
CC   alpha-helices. The cells expressing the receptor are preferably T cells,
CC   B cells, neutrophils, or dendritic cells. The therapeutic cells
CC   expressing the chimeric receptor are administered to a mammal to treat
CC   HIV infection
XX
SQ   Sequence 58 AA;

  Query Match             100.0%;  Score 288;  DB 2;  Length 58;
  Best Local Similarity   100.0%;  Pred. No. 8.5e-22;
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58


RESULT 3
```

```
AAR20806
ID   AAR20806 standard; protein; 240 AA.
XX
AC   AAR20806;
XX
DT   25-MAR-2003  (revised)
DT   21-MAY-1992  (first entry)
XX
DE   Human CD7 antigen coding sequence.
XX
KW   cloning technique; cell surface antigen; immunodiagnosis;
KW   T cell acute lymphoblastic leukaemia; tumour; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   45. .37
FT                   /label= N-linked_glycosylation
FT   Modified-site   96. .98
FT                   /label= N-linked_glycosylation
FT   Region          145. .180
FT                   /label= repeat_region
FT                   /note= "contains 4 repeats of the motif XPPXASALP and may
FT                   act as a stalk to project the V-like domain away from the
FT                   cell surface"
FT   Region          181. .201
FT                   /label= transmembrane
XX
PN   WO9201049-A.
XX
PD   23-JAN-1992.
XX
PF   13-JUL-1990;   90US-00553759.
XX
PR   13-JUL-1990;   90US-00553759.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Seed B,  Aruffo A,  Amiot M;
XX
DR   WPI; 1992-056864/07.
DR   N-PSDB; AAQ21168.
XX
PT   New CD53 cell surface antigen and DNA encoding it - for immuno-therapy
PT   and diagnosis of haematopoietic neoplasms, etc.
XX
PS   Example 4; Fig 8; 160pp; English.
XX
CC   Homology with Ig variable regions predicts the mature terminus of CD7 is
CC   at residue 26. The single cysteine residue in the transmembrane domain
CC   may be the site of fatty acylation. The sequence has substantial homology
CC   with human and mouse Ig kappa chain and T-cell receptor gamma chain
CC   variable regions over almost the entire extracellular portion of the
CC   molecule. The extracellular domain also has significant homology with
CC   both chains of the rat CD8 heterodimer and the myelin P0 protein. A
CC   disulphide bond linking Cys 23 and Cys 89 of the mature protein is
CC   predicted and a second disulphide bond linking Cys 10 and Cys 117 has
CC   also been proposed. (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 2;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 4
AAR91434
ID   AAR91434 standard; protein; 240 AA.
```

```
XX
AC   AAR91434;
XX
DT   25-MAR-2003  (revised)
DT   30-OCT-1996  (first entry)
XX
DE   Human CD7 antigen.
XX
KW   Cell surface antigen; cloning; immunoselection; immunotherapy; therapy;
KW   diagnosis; vector; piH3; CD7; COS; T-lymphocyte.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .27
FT                   /label= Sig_peptide
FT   Modified-site   45. .47
FT                   /label= N-glycosylation_site
FT   Modified-site   96. .98
FT                   /label= N-glycosylation_site
FT   Domain          181. .201
FT                   /label= Transmembrane_domain
XX
PN   US5506126-A.
XX
PD   09-APR-1996.
XX
PF   18-OCT-1993;   93US-00139273.
XX
PR   25-FEB-1988;   88US-00160416.
PR   13-JUL-1989;   89US-00379076.
PR   13-JUL-1990;   90US-00553759.
PR   01-DEC-1992;   92US-00983647.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Seed B,  Aruffo A;
XX
DR   WPI; 1996-200279/20.
DR   N-PSDB; AAT14708.
XX
PT   Cloning of cDNA encoding cell surface antigen - useful for isolation of
PT   diagnostic and therapeutic proteins.
XX
PS   Example 4; Fig 8A-8B; 79pp; English.
XX
CC   The amino acid sequence (AAR91434) of CD7, a cell surface antigen
CC   associated with human T-cells, was deduced from a cDNA clone (AAT14708)
CC   derived from human T-cell tumour HPB-ALL cells. CD7 was expressed in COS
CC   cells following construction of a cDNA library utilising vector piH3 (see
CC   also AAT14702) and panning of the library using antibody-coated plates.
CC   The physiological role of CD7 is unclear; CD7 was demonstrated not be an
CC   IgM receptor. Using the novel immunoselection cloning method, cell
CC   surface antigens (see also AAR91431-46) can be obtd. for diagnostic and
CC   therapeutic use in cases of immune-associated disease, and for
CC   identification, isolation and purification of antibodies and antigens.
CC   (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 2;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 5
AAW80443
ID   AAW80443 standard; protein; 240 AA.
XX
AC   AAW80443;
XX
DT   25-MAR-2003  (revised)
DT   07-JUN-1999  (first entry)
XX
DE   Human CD7 antigen.
XX
KW   CD7; cell surface antigen; human; lymphocyte; cloning;
KW   lymphoblastic leukaemia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   45. .47
FT                   /note= "Asn is N-glycosylated"
FT   Modified-site   96. .98
FT                   /note= "Asn is N-glycosylated"
FT   Domain          181. .201
FT                   /note= "transmembrane domain"
FT   Modified-site   198
FT                   /note= "potential fatty acid esterification site"
XX
PN   US5830731-A.
XX
PD   03-NOV-1998.
XX
PF   21-MAY-1997;   97US-00861205.
XX
PR   25-FEB-1988;   88US-00160416.
PR   13-JUL-1989;   89US-00379076.
PR   23-MAR-1990;   90US-00498809.
PR   13-JUL-1990;   90US-00553759.
PR   01-DEC-1992;   92US-00983647.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Seed B,  Aruffo A;
XX
DR   WPI; 1998-609251/51.
DR   N-PSDB; AAV63446.
XX
PT   New cloning vector and poly:linker - based on existing sequences for
PT   efficient cloning and expression of mammalian cDNA(s), especially human
PT   lymphocyte antigenic sequences.
XX
PS   Example 4; Fig 8A-B; 75pp; English.
XX
CC   This polypeptide comprises human CD7 antigen. Its amino acid sequence was
CC   deduced from the nucleotide sequence (see AAV81204) of a cDNA clone
CC   isolated from HPB-ALL T-cell tumour cells using a novel method for
CC   cloning cDNAs from mammalian expression libraries. The method is based on
CC   transient expression of an antigen in eukaryotic cells and physical
CC   selection of cells expressing the antigen by adhesion to an antibody-
CC   coated substrate. It is useful for the isolation and cloning of any
CC   protein which can be expressed and transported to the cell surface
CC   membrane of a eukaryotic cell, and has been used to clone genes (see
CC   AAV63442-63) encoding cell surface antigens from mammalian lymphocytes
CC   (see AAW80440-55). CD7, a marker for the identification of T cell acute
CC   lymphoblastic leukaemia, has been expressed in COS cells. The purified
CC   genes and proteins are useful for immunodiagnostic and immunotherapeutic
CC   applications, including the diagnosis and treatment of immune-mediated
CC   infections, diseases, and disorders of animals, including humans.
CC   (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 2;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204
```

```
RESULT 6
AAW86190
ID   AAW86190 standard; protein; 240 AA.
XX
AC   AAW86190;
XX
DT   10-MAY-1999  (first entry)
XX
DE   Human CD7 antigen.
XX
KW   CD7; cell surface antigen; human; cDNA library; lymphoblastic leukaemia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   45. .47
FT                   /note= "Asn is N-glycosylated"
FT   Modified-site   96. .98
FT                   /note= "Asn is N-glycosylated"
FT   Domain          181. .201
FT                   /note= "transmembrane domain"
FT   Modified-site   198
FT                   /note= "potential fatty acid esterification site"
XX
PN   US5849898-A.
XX
PD   15-DEC-1998.
XX
PF   07-JUN-1995;   95US-00485447.
XX
PR   25-FEB-1988;   88US-00160416.
PR   13-JUL-1989;   89US-00379076.
PR   23-MAR-1990;   90US-00498809.
PR   13-JUL-1990;   90US-00553759.
PR   01-DEC-1992;   92US-00983647.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Seed B,  Oquendo C,  Camerini D,  Stamenkovic I,  Stengelin S;
PI   Amiot M,  Lauffer L,  Allen J,  Simmons D,  Aruffo A;
XX
DR   WPI; 1999-069813/06.
DR   N-PSDB; AAV81204.
XX
PT   cDNA encoding human CD40 antigen - useful for cloning cDNA encoding cell
PT   surface antigens, constructing cDNA libraries, expressing vectors for
PT   expression in eukaryotic cells or their fragments.
XX
PS   Example 4; Fig 8A-B; 79pp; English.
XX
CC   This polypeptide comprises human CD7 antigen. Its amino acid sequence was
CC   deduced from the nucleotide sequence (see AAV81204) of a cDNA clone
CC   isolated from HPB-ALL T-cell tumour cells using a novel method for
CC   cloning cDNAs from mammalian expression libraries. The method is based on
CC   transient expression of an antigen in eukaryotic cells and physical
CC   selection of cells expressing the antigen by adhesion to an antibody-
CC   coated substrate. It is useful for the isolation and cloning of any
CC   protein which can be expressed and transported to the cell surface
CC   membrane of a eukaryotic cell, and has been used to clone genes (see
CC   AAV81198-220) encoding cell surface antigens such as CD1a, CD1b, CD1c,
CC   CD2, CD6, CD7, CD13, CD14, CD16, CD19, CD20, CD22, CD26, CD27, CD28,
CC   CD31, CDw32a, CDw32b, CD33, CD34, CD36, CD37, CD38, CD39, CD40, CD43,
CC   CD44, CD53, ICAM, LFA-3, FcRIa, FcRIb, TliSa and Leu8 (see AAW86188-62,
CC   AAW89151-52 and AAW88451). CD40 cDNA (see AAV81198) is specifically
CC   claimed. CD7, a marker for the identification of T cell acute
CC   lymphoblastic leukaemia, has been expressed in COS cells
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 2;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 7
AAY96129
ID   AAY96129 standard; protein; 240 AA.
XX
AC   AAY96129;
XX
DT   19-DEC-2000  (first entry)
XX
DE   Human cell surface antigen CD7.
XX
KW   CD7; cell surface antigen; human; immunoselection; panning;
KW   immunodiagnosis; diagnosis; immunotherapy; gene therapy; immune disorder;
KW   infection; asthma; immune-complex disease; amyloidosis;
KW   multiple sclerosis; parasitic disease; leukaemia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Disulfide-bond  10. .117
FT   Disulfide-bond  23. .89
FT   Modified-site   45
FT                   /note= "N-glycosylated"
FT   Modified-site   106
FT                   /note= "N-glycosylated"
FT   Domain          181. .201
FT                   /label= Transmembrane_domain
XX
PN   US6111093-A.
XX
PD   29-AUG-2000.
XX
PF   28-OCT-1998;   98US-00181612.
XX
PR   25-FEB-1988;   88US-00160416.
PR   13-JUL-1989;   89US-00379076.
PR   23-MAR-1990;   90US-00498809.
PR   13-JUL-1990;   90US-00553759.
PR   01-DEC-1992;   92US-00983647.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Stamenkovic I,  Seed B;
XX
DR   WPI; 2000-586382/55.
DR   N-PSDB; AAA50582.
XX
PT   Isolated nucleic acid molecule encoding the CD19 cell surface antigen,
PT   useful for immunodiagnosis and immunotherapy of immune-mediated
PT   infections or disorders, e.g. asthma, immune-complex disease, parasitic
PT   diseases.
XX
PS   Example 4; Fig 8A-B; 75pp; English.
XX
CC   The present sequence is that of human cell surface antigen (CSA) CD7, as
CC   predicted from cDNA isolated from a human T-cell tumour HPB-ALL cDNA
CC   library. The cDNA (see AAA50582) was identified using a new method for
CC   cloning cDNAs encoding CSAs. The method is based upon transient
CC   expression of CSA in eukaryotic cells and physical selection of cells
CC   expressing the CSA by adhesion to (panning on) an antibody-coated
CC   substrate such as a culture dish. The predicted amino acid sequence of
CC   CD7 reveals substantial homology in the extracellular region to human and
CC   mouse immunoglobulin kappa chain and T-cell receptor gamma chain variable
CC   regions. CD7 is a marker for T-cell acute lymphoblastic leukaemia. The
CC   CSA nucleic acids isolated by the novel method, and the proteins they
CC   encode, are useful for immunodiagnostic and immunotherapeutic
CC   applications, including the diagnosis and treatment of immune-mediated
```

```
CC   infections, diseases, and disorders in animals, including humans. These
CC   disorders include asthma, immune-complex disease, amyloidosis, parasitic
CC   diseases or multiple sclerosis
XX
SQ   Sequence 240 AA;

  Query Match            98.6%;  Score 284;  DB 3;  Length 240;
  Best Local Similarity  98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 8
AAU02438
ID   AAU02438 standard; protein; 240 AA.
XX
AC   AAU02438;
XX
DT   09-SEP-2004  (revised)
DT   29-AUG-2001  (first entry)
XX
DE   Human lymphocyte cell surface antigen CD7 polypeptide.
XX
KW   Human; lymphocyte cell surface antigen; immune-mediated disease; CD7;
KW   infection; immune deficiency disorder; hypersensitivity; inflammation;
KW   systemic lupus erythematosus; platelet disorder; rheumatoid arthritis;
KW   transplant rejection; asthma.
XX
OS   Homo sapiens.
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   45. .47
FT                   /note= "Asn is glycosylated"
FT   Modified-site   96. .98
FT                   /note= "Asn is glycosylated"
FT   Domain          181. .201
FT                   /label = Transmembrane_domain
FT   Modified-site   198
FT                   /note= "Fatty acid esterification site"
XX
PN   US6218525-B1.
XX
PD   17-APR-2001.
XX
PF   01-DEC-1992;   92US-00983647.
XX
PR   25-FEB-1988;   88US-00160416.
PR   13-JUL-1989;   89US-00379076.
PR   13-JUL-1990;   90US-00553759.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Seed B,  Aruffo A,  Simmons D;
XX
DR   WPI; 2001-289848/30.
DR   N-PSDB; AAS03176.
XX
PT   New recombinant DNA encoding CD28 useful for diagnosing and treating
PT   immune-mediated diseases, infections or disorders, e.g. systemic lupus
PT   erythematosus, asthma, transplant rejection, rheumatoid arthritis.
XX
PS   Example 4; Fig 8A-8B; 72pp; English.
XX
CC   The present sequence representing human lymphocyte cell surface antigen
CC   CD7 is 1 of various human lymphocyte cell surface antigen polypeptide
CC   sequences (AAU02435-AAU02452) described in the present invention. The
CC   invention relates to a novel method of cloning cDNA encoding cell surface
CC   antigens and efficient construction of cDNA libraries. Also described are
CC   2 expression vectors (AAS03171, AAS03174) which provide high level
CC   expression in eukaryotic host cells. A genetically engineered cDNA
CC   sequence encoding the CD28 amino acid extracellular domain sequence
CC   (amino acids 1-134 given in AAU02437) and/or comprising nucleotides 100-
CC   759, 154-555 or 154-759 of the CD28 cDNA sequence (AAS03175) is also new.
CC   The purified genes and proteins are useful for immunodiagnostic and
CC   immunotherapeutic applications, such as in the diagnosis and treatment of
CC   immune-mediated diseases, infections or disorders in animals and humans.
CC   Such diseases include immune deficiency diseases, diseases of immediate
CC   type of hypersensitivity, asthma, hypersensitivity pneumonitis, systemic
CC   lupus erythematosus, rheumatoid arthritis, acute and chronic
CC   inflammation, platelet disorders, plasma and other cell neoplasms,
CC   parasitic diseases, multiple sclerosis, Guillain-Barre syndrome and
CC   tissue and organ transplant rejection. The sequences can also be used to
CC   identify, isolate and purify other antibodies and antigens
CC
CC   Revised record issued on 09-SEP-2004 : Correction to feature table key
XX
SQ   Sequence 240 AA;

  Query Match            98.6%;  Score 284;  DB 4;  Length 240;
  Best Local Similarity  98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 9
AAB36657
ID   AAB36657 standard; protein; 240 AA.
XX
AC   AAB36657;
XX
DT   13-MAR-2001  (first entry)
XX
DE   Human CD7 protein sequence SEQ ID NO:2.
XX
KW   Human; CD7; K12; cognate ligand; cluster of differentiation; cancer;
KW   identification; inhibiting T cell proliferation; HIV; infection;
KW   activating natural killer cell proliferation; leukaemia; lymphoma;
KW   sepsis; graft versus host disease; autoimmune disease; arthritis;
KW   multiple sclerosis; rheumatoid arthritis; psoriatic arthritis; lupus;
KW   scleroderma; psoriasis; atopic dermatitis; type I diabetes mellitus;
KW   Hashimoto's thyroiditis; pernicious anaemia; Addison's disease; uveitis;
KW   myasthenia gravis; psoriasis; Guillain-Barre Syndrome; Grave's disease;
KW   systemic lupus erythematosus; dermatomyositis; asthma; eczema;
KW   atopical dermatitis; contact dermatitis; eczematous dematitide;
KW   seborrhoeic dermatitis; rhinitis.
XX
OS   Homo sapiens.
XX
PN   WO200073333-A2.
XX
PD   07-DEC-2000.
XX
PF   26-MAY-2000; 2000WO-US014612.
XX
PR   28-MAY-1999;   99US-0136450P.
XX
PA   (IMMV ) IMMUNEX CORP.
XX
PI   Lyman SD,  Fanslow WC;
XX
DR   WPI; 2001-061511/07.
DR   N-PSDB; AAC88151.
XX
PT   Stimulating intracellular signaling of CD7 comprises contacting a cell
PT   expressing CD7 with recombinant K12 protein, the cognate ligand of CD7,
PT   to inhibit T cell proliferation and/or activate natural killer cell
PT   proliferation.
XX
PS   Disclosure; Page 35-36; 42pp; English.
```

```
XX
CC   The present invention describes a method for stimulating (S) the
CC   intracellular signalling of CD (cluster of differentiation) 7 comprising
CC   contacting a cell that expresses CD7 with a recombinant K12 protein (I),
CC   the cognate ligand of CD7. (S) is useful for inhibiting T cell
CC   proliferation and/or activating NK (natural killer) cell proliferation
CC   and/or inducing NK toxicity in a mammal which involves administration of
CC   K12 protein. It is also used for treating HIV-1 infection, cancer (T cell
CC   leukaemia, acute lymphomic leukaemia, cutaneous T cell lymphoma),
CC   bacterial and viral infections, mediated by CD7. In the case of treating
CC   T cell leukaemia the soluble K12 protein is covalently attached to a
CC   toxin. A disease mediated by CD7 such as sepsis, graft versus host
CC   disease due to transplantation, autoimmune diseases, multiple sclerosis,
CC   arthritis, rheumatoid arthritis, psoriatic arthritis, scleroderma, lupus,
CC   psoriasis, atopic dermatitis, type I diabetes mellitus, Hashimoto's
CC   thyroiditis, pernicious anaemia, Addison's disease, myasthenia gravis,
CC   uveitis, psoriasis, Guillain-Barre Syndrome, Grave's disease, systemic
CC   lupus erythematosus and dermatomyositis, asthma, eczema, atopical
CC   dermatitis, contact dermatitis, other eczematous dematitides, seborrhoeic
CC   dermatitis, and rhinitis is also treated by administering a K12
CC   antagonist (neutralising antibody). The present sequence represents the
CC   human CD7 protein, which is given in the exemplification of the present
CC   invention
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 4;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 10
ADO49346
ID   ADO49346 standard; protein; 240 AA.
XX
AC   ADO49346;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human CD7 antigen.
XX
KW   cell surface antigen; immune-mediated disorder; asthma;
KW   rheumatoid arthritis; multiple sclerosis; vasculitis; inflammation;
KW   human.
XX
OS   Homo sapiens.
XX
PN   US2004072283-A1.
XX
PD   15-APR-2004.
XX
PF   17-APR-2001; 2001US-00836544.
XX
PR   25-FEB-1988;   88US-00160416.
PR   13-JUL-1989;   89US-00379076.
PR   23-MAR-1990;   90US-00498809.
PR   13-JUL-1990;   90US-00553759.
PR   01-DEC-1992;   92US-00983647.
XX
PA   (SEED/) SEED B.
PA   (ALLE/) ALLEN J.
PA   (ARUF/) ARUFFO A.
PA   (CAME/) CAMERINI D.
PA   (LAUF/) LAUFFER L.
PA   (OQUE/) OQUENDO C.
PA   (SIMM/) SIMMONS D.
PA   (STAM/) STAMENKOVIC I.
PA   (STEN/) STENGELIN S.
PA   (AMIO/) AMIOT M.
XX
PI   Seed B,  Allen J,  Aruffo A,  Camerini D,  Lauffer L,  Oquendo C;
PI   Simmons D,  Stamenkovic I,  Stengelin S,  Amiot M;
XX
DR   WPI; 2004-328571/30.
DR   N-PSDB; ADO49345.
XX
PT   New cloning cDNA segments encoding cell surface antigens of human
PT   lymphocytes, useful in diagnosing and treating asthma, rheumatoid
PT   arthritis, multiple sclerosis, vasculitis and inflammation and
PT   infections.
XX
PS   Claim 2; Fig 8; 75pp; English.
XX
CC   The invention relates to a cloned cDNA segment encoding a cell surface
CC   antigen selected from CD1a, CD1b, CD1c, CD2, CD6, CD7, CD13, CD14, CD16,
CC   CD19, CD20, CD22, CD26, CD27, CD31, CD2w32a, CDw32b, CD33, CD34, CD36,
CC   CD37, CD38, CD39, CD40, CD43 and their functional derivatives. The cell
CC   surface antigens of human lymphocytes prepared from the cDNAs are useful
CC   in diagnostic and therapeutic utility in immune-mediated disorders
CC   (asthma, rheumatoid arthritis, multiple sclerosis, vasculitis and
CC   inflammation) and infections in mammals, including humans. The present
CC   sequence represents the amino acid sequence of a human cell surface
CC   antigen.
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 8;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 11
ADP55090
ID   ADP55090 standard; protein; 240 AA.
XX
AC   ADP55090;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Human PRO protein sequence SEQ ID NO:1066.
XX
KW   human; PRO; immune related disease; inflammatory immune response;
KW   immune response stimulation; antiallergic; antianaemic; antiarthritic;
KW   antiasthmatic; antidiabetic; antiinflammatory; antipsoriatic;
KW   antirheumatic; antithyroid; CNS; dermatological; gastrointestinal;
KW   haemostatic; hepatotropic; immunostimulant; immunosuppressive; muscular;
KW   nephrotropic; neuroprotective; osteopathic; respiratory; vasotropic;
KW   virucide; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO2004039956-A2.
XX
PD   13-MAY-2004.
XX
PF   28-OCT-2003; 2003WO-US034381.
XX
PR   29-OCT-2002; 2002US-0422472P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Aggarwal S,  Clark H,  Gurney AL,  Schoenfeld J,  Williams PM;
PI   Wood WI,  Wu TD;
XX
DR   WPI; 2004-376182/35.
DR   N-PSDB; ADP55089.
XX
PT   New PRO polynucleotides and polypeptides, useful in useful in diagnosing
```

```
PT   and treating an immune related disease, e.g. systemic lupus
PT   erythematosus, rheumatoid arthritis, diabetes mellitus or asthma and in
PT   stimulating an immune response.
XX
PS   Claim 1; SEQ ID NO 1066; 3009pp; English.
XX
CC   The present invention describes an isolated PRO nucleic acid (I). Also
CC   described: (1) a vector comprising (I); (2) a host cell comprising the
CC   vector of (1); (3) a process for producing a PRO polypeptides; (4) an
CC   isolated PRO polypeptide; (5) a chimeric molecule comprising the
CC   polypeptide of (4) fused to a heterologous amino acid sequence; (6) an
CC   antibody which specifically binds to a polypeptide of (4); (7) a
CC   composition of matter comprising a polypeptide of (4), an agonist or
CC   antagonist of the polypeptide or an antibody that binds to the
CC   polypeptide in combination with a carrier; (8) an article of manufacture
CC   comprising a container, a label on the container and a composition of
CC   matter of (7); (9) a method of treating an immune related disease in a
CC   mammal; (10) a method for determining the presence of a PRO polypeptide
CC   in a sample suspected of having the polypeptide; (11) a method of
CC   diagnosing an immune related disease or an inflammatory immune response
CC   in mammal; (12) a method of identifying a compound that inhibits or
CC   mimics the activity of or expression of a gene encoding a PRO polypeptide
CC   ; and (13) a method of stimulating the immune response in a mammal. The
CC   PRO sequences have antiallergic, antianaemic, antiarthritic,
CC   antiasthmatic, antidiabetic, antiinflammatory, antipsoriatic,
CC   antirheumatic, antithyroid, CNS, dermatological, gastrointestinal,
CC   haemostatic, hepatotropic, immunostimulant, immunosuppressive, muscular,
CC   nephrotropic, neuroprotective, osteopathic, respiratory, vasotropic and
CC   virucide activities, and can be used in gene therapy. The nucleic acid
CC   (I) and the encoded polypeptides, compositions, kits and methods are
CC   useful in diagnosing and treating an immune related disease and in
CC   stimulating an immune response. The present sequence represents a human
CC   PRO protein from the present invention.
XX
SQ   Sequence 240 AA;

  Query Match             98.6%;  Score 284;  DB 8;  Length 240;
  Best Local Similarity   98.3%;  Pred. No. 9.3e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        147 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 204


RESULT 12
ADI60167
ID   ADI60167 standard; protein; 250 AA.
XX
AC   ADI60167;
XX
DT   15-APR-2004  (first entry)
XX
DE   Secreted polypeptide #51.
XX
KW   osteopathic; vulnerary; cytostatic; gene therapy; diagnosis; forensics;
KW   gene mapping; mutation identification; biodiversity; chromosome marker;
KW   immune response; myeloid cell disorder; lymphoid cell disorder;
KW   bone cartilage; tendon; ligament; nerve tissue growth; wound healing;
KW   burns; incision; ulcer; cancer.
XX
OS   Homo sapiens.
XX
PN   WO2003025142-A2.
XX
PD   27-MAR-2003.
XX
PF   18-SEP-2002; 2002WO-US029636.
XX
PR   18-SEP-2001; 2001US-0323349P.
PR   16-SEP-2002; 2002US-00323349.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Asundi V,  Goodrich RW,  Ren F,  Zhang J,  Zhao QA,  Wang J;
PI   Ghosh M,  Xue AJ,  Wehrman T,  Weng G,  Zhou P,  Drmanac RT;
XX
DR   WPI; 2003-354601/33.
DR   N-PSDB; ADI60512.
XX
PT   New polynucleotides and secreted proteins, useful for treating myeloid or
PT   lymphoid cell disorders, in bone cartilage, tendon, ligament and nerve
PT   tissue growth or regeneration, in wound healing, and in tissue repair and
PT   replacement.
XX
PS   Claim 20; SEQ ID NO 202; 243pp; English.
XX
CC   The invention relates to novel isolated polynucleotides or a sequence
CC   encoding a polypeptide with biological activity, where the polynucleotide
CC   hybridizes to the polynucleotide under stringent hybridization conditions
CC   or has greater than 99% sequence identity with the polynucleotide. The
CC   polynucleotides and polypeptides are useful in diagnostics, forensics,
CC   gene mapping, identification of mutations responsible for genetic
CC   disorders and other traits, to assess biodiversity, as nutritional
CC   sources or supplements. The polynucleotides may also be used as molecular
CC   weight markers, chromosome markers or map related gene positions, or as
CC   an antigen to raise anti-DNA antibodies or elicit immune response. The
CC   polypeptides are useful for raising antibodies, as markers for tissues in
CC   which the corresponding polypeptide is expressed, for re-engineering
CC   damaged or diseased tissues, for treating myeloid or lymphoid cell
CC   disorders, in bone cartilage, tendon, ligament and/or nerve tissue growth
CC   or regeneration, in wound healing, in tissue repair and replacement, in
CC   healing of burns, incisions and ulcers, and in treating cancer. This
CC   sequence corresponds to a protein sequence of the invention.
XX
SQ   Sequence 250 AA;

  Query Match             98.6%;  Score 284;  DB 7;  Length 250;
  Best Local Similarity   98.3%;  Pred. No. 9.7e-21;
  Matches   57;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||:
Db        157 PRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 214


RESULT 13
ADS11080
ID   ADS11080 standard; protein; 225 AA.
XX
AC   ADS11080;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human therapeutic protein - SEQ ID 1317.
XX
KW   antiinflammatory; neuroprotective; antianaemic; cytostatic; vulnerary;
KW   inflammatory; haematopoiesis; immunity; neurodegenerative; stem cell;
KW   aplastic anaemia; cancer; wound healing; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO2004080148-A2.
XX
PD   23-SEP-2004.
XX
PF   30-SEP-2003; 2003WO-US030720.
XX
PR   02-OCT-2002; 2002US-0416186P.
XX
PA   (NUVE-) NUVELO INC.
XX
PI   Tang YT,  Asundi V,  Ren F,  Zhang J,  Wehrman T,  Wang Z,  Ma Y;
PI   Wang D,  Chen R,  Zhao QA,  Wang J,  Ghosh M,  Xue AJ,  Weng G,  Zhou P;
XX
DR   WPI; 2004-668857/65.
```

DR N-PSDB; ADS10396.
XX
PT New polynucleotide, useful in preparing a composition for diagnosing or
PT treating inflammatory, neurodegenerative or stem cell disorders, e.g.,
PT aplastic anemia or cancer for promoting wound healing.
XX
PS Claim 20; SEQ ID NO 1317; 718pp; English.
XX
CC The invention relates to a novel isolated polynucleotide and the encoded
CC polypeptide. The molecules of the invention demonstrate antiinflammatory,
CC neuroprotective, antianaemic, cytostatic and vulnerary activities and may
CC be useful in preparing a composition for diagnosing or treating
CC inflammatory, haematopoietic, immune, neurodegenerative or stem cell
CC disorders, such as aplastic anaemia or cancer, as well as for promoting
CC wound healing. The molecules may also be utilised during gene therapy
CC procedures. The current sequence is that of a human therapeutic protein
CC of the invention. The current sequence is not shown explicitly within the
CC specification but can be accessed from the WIPO web-site.
XX
SQ Sequence 225 AA;

Query Match 67.0%; Score 193; DB 8; Length 225;
Best Local Similarity 82.4%; Pred. No. 1.3e-11;
Matches 42; Conservative 1; Mismatches 2; Indels 6; Gaps 1;

Qy 8 APPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTR 58
||| |||| ||||||||||||||||||||||||||||||||:
Db 145 APPRASALP------ALPDPPAASALPAALAVISFLLGLGLGVACVLARTQ 189

RESULT 14
AAW35850
ID AAW35850 standard; protein; 154 AA.
XX
AC AAW35850;
XX
DT 27-APR-1998 (first entry)
XX
DE Human CD7 for use in T lymphocyte veto molecule.
XX
KW Human; CD7; T lymphocyte veto molecule; chimeric molecule;
KW targetting polypeptide; suppression; immune response; treatment;
KW autoimmune disease; allergy; immunological disorder;
KW transplant rejection.
XX
OS Homo sapiens.
XX
PN WO9737687-A1.
XX
PD 16-OCT-1997.
XX
PF 10-APR-1997; 97WO-US005943.
XX
PR 10-APR-1996; 96US-00630172.
XX
PA (NAJE-) NAT JEWISH CENT IMMUNOLOGY & RESPIRATORY.
XX
PI Staerz UD;
XX
DR WPI; 1997-512419/47.
XX
PT T lymphocyte veto molecule comprising response cell activating protein -
PT linked to molecule that targets stimulator cell marker, used for
PT selective suppression of immune response, e.g. prevention of graft
PT rejection or treatment of auto-immune disease.
XX
PS Claim 37; Page 60; 309pp; English.
XX
CC A novel T lymphocyte veto molecule is a chimeric molecule comprising a
CC protein, e.g. the present sequence, linked to a targetting polypeptide
CC that binds a molecule, which differentiates a host cell from a tissue
CC graft cell, or selectively targets a stimulator cell involved in the
CC autoimmune response. A veto molecule, in which the protein binds a
CC molecule that targets stimulator cells, can be used to suppress an immune
CC response and therefore treat autoimmune diseases, e.g. systemic lupus
CC erythematosus, myasthenia gravis, rheumatoid arthritis, insulin dependent
CC diabetes mellitus, multiple sclerosis, coeliac disease, autoimmune
CC thyroiditis, Addison's or Grave's diseases and rheumatoid carditis,
CC allergies and other immunological disorders. Where the protein binds a
CC molecule that differentiates graft and host cells, the veto molecule can
CC be used to reduce transplant rejection. The veto molecule provides
CC specific regulation of particular stimulator cells that can kill graft
CC cells or respond to autoantigens, but leave other stimulator cells
CC unaffected, e.g. CD4 or CD8 positive cells can be regulated without one
CC affecting the other. The veto molecule can be administered locally to
CC minimise generalised immunosuppression
XX
SQ Sequence 154 AA;

Query Match 61.1%; Score 176; DB 2; Length 154;
Best Local Similarity 100.0%; Pred. No. 4.6e-10;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRASALPAPPTGSALPDPQTASALPDPPAASALP 34
||||||||||||||||||||||||||||||||||
Db 121 PRASALPAPPTGSALPDPQTASALPDPPAASALP 154

RESULT 15
ABB71046
ID ABB71046 standard; protein; 145 AA.
XX
AC ABB71046;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 39930.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US009231.
XX
PR 23-MAR-2000; 2000US-0191637P.
PR 11-JUL-2000; 2000US-00614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL15149.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signaling and cell-cell
PT interactions.
XX
PS Disclosure; SEQ ID NO 39930; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 145 AA;

Query Match 29.0%; Score 83.5; DB 4; Length 145;
Best Local Similarity 44.1%; Pred. No. 0.91;
Matches 26; Conservative 5; Mismatches 21; Indels 7; Gaps 4;

```
Qy          4 SALPAPPT--GSALPDPQTASALPDPPAAS--ALPAALAV-ISFLLGLGLGVACVLART 57
              ||  | ||  ||| | |   |  |:|||     ||  | : :  ||:|:||   | ||
Db         33 SAATATPTASGSATPTPSPTS--PNPPAVGGMGLPMPLTLGLGLGLGMGMGVVSRLRRT 89
```

Search completed: March 7, 2005, 07:13:05
Job time : 26.409 secs